MA52365A - Composés et leurs utilisations - Google Patents

Composés et leurs utilisations

Info

Publication number
MA52365A
MA52365A MA052365A MA52365A MA52365A MA 52365 A MA52365 A MA 52365A MA 052365 A MA052365 A MA 052365A MA 52365 A MA52365 A MA 52365A MA 52365 A MA52365 A MA 52365A
Authority
MA
Morocco
Prior art keywords
compounds
Prior art date
Application number
MA052365A
Other languages
English (en)
Inventor
Bertrand Le Bourdonnec
Matthew Lucas
Kerem Ozboya
Bhaumik Pandya
Daniel Tardiff
Parcharee Tivitmahaisoon
Iwona Wrona
Original Assignee
Yumanity Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yumanity Therapeutics Inc filed Critical Yumanity Therapeutics Inc
Publication of MA52365A publication Critical patent/MA52365A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA052365A 2018-04-25 2019-04-24 Composés et leurs utilisations MA52365A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862662673P 2018-04-25 2018-04-25

Publications (1)

Publication Number Publication Date
MA52365A true MA52365A (fr) 2021-03-03

Family

ID=68290767

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052365A MA52365A (fr) 2018-04-25 2019-04-24 Composés et leurs utilisations

Country Status (6)

Country Link
US (1) US10919885B2 (fr)
EP (1) EP3784234A1 (fr)
JP (1) JP2021522253A (fr)
CN (1) CN112566636A (fr)
MA (1) MA52365A (fr)
WO (1) WO2019209962A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018081167A1 (fr) 2016-10-24 2018-05-03 Yumanity Therapeutics Composés et utilisations de ces derniers
CA3083000A1 (fr) 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. Composes et utilisations de ces composes
CA3127791A1 (fr) 2019-01-24 2020-07-30 Yumanity Therapeutics, Inc. Composes et leurs utilisations
CA3157173A1 (fr) * 2019-10-09 2021-04-15 Praxis Biotech LLC Modulateurs atf6 et leurs utilisations
MX2022004212A (es) * 2019-10-09 2022-06-08 Praxis Biotech LLC Moduladores de atf6 y usos de los mismos.
WO2022049134A1 (fr) 2020-09-03 2022-03-10 F. Hoffmann-La Roche Ag Composés hétérocycliques
TW202309010A (zh) * 2021-04-23 2023-03-01 瑞士商赫孚孟拉羅股份公司 新穎雜環化合物

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2495179A1 (fr) 2002-08-09 2004-02-19 Astrazeneca Ab Nouveaux composes
US8207147B2 (en) 2003-12-24 2012-06-26 Prosidion Limited Heterocyclic derivatives as GPCR receptor agonists
AU2005266313B2 (en) 2004-07-26 2011-08-25 Merck Serono Sa N-hydroxyamide derivatives and use thereof
TW200626154A (en) 2004-09-20 2006-08-01 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
TW200626155A (en) 2004-09-20 2006-08-01 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
CA2610196A1 (fr) 2005-06-09 2006-12-14 Merck Frosst Canada Ltd. Derives d'azacyclohexane comme inhibiteurs de la stearoyl-coenzyme a delta-9 desaturase
PE20071221A1 (es) 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
EP2032566A4 (fr) 2006-06-12 2009-07-08 Merck Frosst Canada Ltd Dérivés d'azétidine comme inhibiteurs de la stéaroyl-coenzyme a delta-9 désaturase
CA2672776A1 (fr) * 2006-12-20 2008-06-26 Novartis Ag Composes organiques
CA2697551C (fr) 2007-09-20 2013-03-12 Irm Llc Composes et compositions en tant que modulateurs de l'activite de gpr119
GB0722077D0 (en) 2007-11-09 2007-12-19 Smithkline Beecham Corp Compounds
WO2009086303A2 (fr) * 2007-12-21 2009-07-09 University Of Rochester Procédé permettant de modifier la durée de vie d'organismes eucaryotes
MX2010010241A (es) 2008-03-20 2010-12-06 Forest Lab Holdings Ltd Derivados de piperidina novedosos como inhibidores de estearoil-coa desaturasa.
TWI434842B (zh) 2008-07-14 2014-04-21 Astellas Pharma Inc Azole compounds
WO2010022055A2 (fr) 2008-08-20 2010-02-25 Amgen Inc. Inhibiteurs de canaux sodiques sensibles au potentiel
WO2010039186A2 (fr) 2008-09-23 2010-04-08 Renovis, Inc. Composés utiles en tant que modulateurs de la faah et leurs utilisations
US20120010186A1 (en) 2009-03-23 2012-01-12 Merck Frosst Canada Ltd. Heterocyclic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
ES2555224T3 (es) 2009-12-23 2015-12-29 Jasco Pharmaceuticals Llc Inhibidores de aminopirimidina cinasa
BR112014003963A2 (pt) 2011-09-01 2017-03-21 Irm Llc compostos e composições como inibidores de quinase c-kit
CA2850836A1 (fr) 2011-10-15 2013-04-18 Genentech, Inc. Procedes d'utilisation d'antagonistes de scd1
US20130225529A1 (en) 2012-02-27 2013-08-29 Basil Rigas Phospho-ester derivatives and uses thereof
CN104703980B (zh) 2012-10-10 2017-09-22 埃科特莱茵药品有限公司 属于[邻双(杂)芳基]‑[2‑(间双(杂)芳基)吡咯烷‑1‑基]甲酮衍生物的食欲素受体拮抗剂
WO2016129583A1 (fr) * 2015-02-09 2016-08-18 国立大学法人岡山大学 Inhibiteur de la lactate déshydrogénase et médicament antiépileptique le contenant
WO2018081167A1 (fr) 2016-10-24 2018-05-03 Yumanity Therapeutics Composés et utilisations de ces derniers

Also Published As

Publication number Publication date
CN112566636A (zh) 2021-03-26
EP3784234A1 (fr) 2021-03-03
US10919885B2 (en) 2021-02-16
US20190330198A1 (en) 2019-10-31
JP2021522253A (ja) 2021-08-30
WO2019209962A8 (fr) 2020-04-09
WO2019209962A1 (fr) 2019-10-31

Similar Documents

Publication Publication Date Title
MA50256A (fr) Composés de pyrazolopyrimidinone et leurs utilisations
MA50618A (fr) Polyrhérapies et leurs utilisations
MA52483A (fr) Dérivés de gip et leurs utilisations
MA43205A (fr) Composés pyy sélectifs et leurs utilisations
MA54555A (fr) Agonistes de glp-1r et leurs utilisations
MA52365A (fr) Composés et leurs utilisations
MA41598A (fr) Composés thérapeutiques de pyridazine et leurs utilisations
MA50173A (fr) Composés activateurs de bisamide sarcomère et leurs utilisations
MA46990A (fr) Compositions de glp-1 et leurs utilisations
MA49537A (fr) Anticorps anti-lag3 et leurs utilisations
MA47789A (fr) Anticorps anti-phf-tau et leurs utilisations
MA55385A (fr) Composés et leurs utilisations
MA42622A (fr) Agents de liaison à tigit et leurs utilisations
MA45943A (fr) Compositions ignifuges et leurs utilisations
MA46471A (fr) Protéines actriib à variant et leurs utilisations
MA43284A (fr) Composés et leurs méthodes d'utilisation
MA52092A (fr) Composés et leurs utilisations
MA49047A (fr) Composés inhibiteurs d'ask1 et utilisations associées
MA45125A (fr) Anticorps anti-alpha-synucléine et leurs utilisations
MA55083A (fr) Polyribonucléotides et leurs utilisations cosmétiques
MA43567A (fr) Anticorps pacap et leurs utilisations
MA49886A (fr) Anticorps anti-par2 et leurs utilisations
MA45857A (fr) Composés et compositions, et utilisations associées
MA43141A (fr) Nouveaux composés et leurs utilisations
MA48956A (fr) Composés mic-1 et utilisations associées